Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Venetoclax showed promising activity in a small phase II trial in relapsed/refractory Waldenström macroglobulinemia (WM). To report the clinical activity of venetoclax and prognostic factors associated with outcomes in a larger cohort, we retrospectively identified 76 patients with relapsed/refractory lymphoplasmacytic lymphoma (LPL)/WM treated with venetoclax monotherapy at nine US medical centers. The median age at venetoclax treatment initiation was 66 years.
Introduction: The prognosis of histological transformation (HT) in Waldenström macroglobulinemia (WM) is unfavourable despite the use of diffuse large B-cell lymphoma-directed chemo-immunotherapy. The aim of this study was to evaluate the outcomes after autologous stem-cell transplantation (autoSCT) or allogeneic stem-cell transplantation (alloSCT) in patients with transformed WM.
EGFR mutation in squamous cell carcinoma of lung - Does it carry the same connotation as in adenocarcinomas? S. Zanwar1, A. Joshi1, V. Noronha1, V. Patil1, A. Chougule1, S. Kane2, R. Kumar2 and K. Prabhash1 1Medical Oncology, Tata Memorial Hospital Centre, Mumbai, India 2Pathology, Tata Memorial Hospital Centre, Mumbai, India Background: EGFR Tyrosine Kinase Inhibitiors (TKIs) have greatly improved outcomes of EGFR mutation positive Adenocarcinomas of lung.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
